|Security||ILIU / Interleukin Genetics, Inc. (458738101)|
|Industry||In Vitro and In Vivo Diagnostic Substances|
|CEO||Carbeau Mark B|
|Institutional Shares||47,928,111 - 11.11%|
|Common Stock Capital Shares Outstanding Reserved For Future Issuance||431,276,871 shares (as of 2017-03-31)|
|Institutional Value||$ 1,000 USD|
Institutional Stock Ownership and Shareholders
Interleukin Genetics, Inc. (OTC:ILIU) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 47,928,111 shares. Largest shareholders include Pyxis Innovations Inc, and Cpcm, Llc.
Interleukin Genetics, Inc. (OTC:ILIU) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Stop missing out on important events!
|File Date||Form||Investor||Opt||Prev Shares||Current Shares||Change
|Prev Value (x$1000)||Current Value (x$1000)||Change|
|PYXIS INNOVATIONS INC||47,625,840||47,625,840||0.00|